Ultherapy Side Effects, Honestly: What's Common and What's Not

The honest answer is that Ultherapy side effects fall into three tiers — common and self-limited, uncommon but documented, and rare but real — and the brochure version of the answer collapses all three into the same sentence about minimal downtime. That collapse is what makes the question hard to research as a foreign patient, because the patient forums are full of stories from all three tiers without much sorting. So I have done the sorting in my own notebook over three procedures in Gangnam, and I have cross-checked the published literature where I can. I want to flag the hedging up front: my experience reflects one face on three procedures, and your face, your provider's parameters, and your skin type will all shift the details. The structure of the tier list, though, travels. The exact incidence numbers in any single study do not.

What counts as an Ultherapy side effect, technically

An Ultherapy side effect is any unintended physiological response to microfocused ultrasound energy delivered at depth in the skin and superficial musculoaponeurotic system, ranging from expected transient surface effects (erythema, edema, mild tenderness) to uncommon documented effects (transient welts, patchy paresthesia, post-inflammatory hyperpigmentation in darker skin types) to rare but reported events (motor nerve weakness from inadvertent deep energy delivery, focal volume loss in lean faces, nodular fibrosis). That is the technical definition, and the reason it is worth being precise about it is that the colloquial use of the phrase covers everything from "my face was warm for an hour" to "my smile was asymmetric for six weeks." Those are not the same thing, and conflating them is what makes the brochure read as either reassuring or terrifying depending on which patient story you read first.

The peer-reviewed literature on Ultherapy and MFU safety is meaningful, though smaller than the literature on the procedure's efficacy. The 2014 review in Clinical, Cosmetic and Investigational Dermatology by Fabi summarized the typical side-effect profile as mild and self-limited in the majority of patients. Alster and Tanzi (Dermatologic Surgery, 2015) reported a series with a transient-welt incidence in the low single digits and rare cases of motor weakness that resolved within weeks. A 2020 paper in the Journal of Cosmetic and Laser Therapy on long-term MFU safety reported that serious adverse events are uncommon and that most are operator-dependent rather than device-dependent. Studies suggest the side-effect profile is closely tied to who is holding the transducer, which is one of the reasons clinic selection matters more than device selection in my own decision-making.

Tier one: common and self-limited (what almost everyone gets)

Tier one is the set of side effects that almost everyone experiences at some level, and that resolve within hours to days without intervention. In my notebook from three procedures: mild swelling along the lower jawline and cheeks (peak at Day 1, mostly resolved by Day 3); transient pinkness or flush in the treated zones (visible to me in the bathroom mirror Day 0 and Day 1, mostly invisible to other people by Day 2); patchy tenderness when pressing the side of the face (most pronounced Day 1 to Day 3, fading through Day 7); jaw stiffness when yawning or chewing aggressively (Day 1 through Day 5, fully gone by Day 7 to Day 10); and a brief warm sensation in the treated zones for the first one to three hours after leaving the clinic, like the end of a long sun day without enough sunscreen.

What the literature says about tier one: Fabi 2014 and several follow-up reviews report that more than 90 percent of MFU patients experience some combination of these effects, that the effects are self-limited in the vast majority, and that no specific intervention is required beyond cool compress and gentle skincare. Patients report (and my own three procedures confirm) that the timeline for tier one is consistent — peak swelling at 24 to 48 hours, mostly resolved by Day 3 to Day 7, fully resolved by Day 14. The variability is in the intensity, not the timeline. My second procedure had more visible swelling than my first because the line count was higher; the timeline was identical.

The one thing about tier one that I think is under-communicated: the brochure phrase "no visible downtime" is technically accurate at the level of a stranger on the street, but not accurate at the level of you in a bathroom mirror at 8am on Day 1 or in a flash photograph at a wedding on Day 4. If you are scheduling around a public event, push the event to Day 10 or later, not Day 4. Studio lighting and a Sigma 85mm at f/1.4 will pick up residual flush that real life will not. May help is the framing here — the timing optimization is a small lever, but it is real.

Tier two: uncommon but documented (the welt question and the numbness question)

Tier two is the set of side effects that show up in a meaningful minority of patients — somewhere in the single-digit to low-double-digit percent range across published series, depending on the parameters and the protocol — and that resolve over days to weeks rather than hours to days. Three of these come up most often in my own notebook and in the patient forums I read, and they are the ones I want to address with actual numbers rather than reassurance.

The welt question. I have had a small linear welt on the lateral cheek twice across three procedures. The welt looks like a slightly raised, slightly red track about three to five centimeters long, along the line of one of the transducer passes. It is unsettling the first time you see it, and the patient forums are full of distressed Day 1 photos of welts that read like serious injuries. The Alster and Tanzi 2015 series reported transient welts as a known but uncommon side effect with reported incidence in the low single digits across their patient population, resolving within 24 to 72 hours without intervention. Mine have always cleared by Day 3 with cool compress, no heat, no active skincare. If a welt persists past 72 hours, becomes painful, or spreads, that is a same-day clinic call.

The numbness question. Mild patchy numbness or a tingling sensation in the treated area for a few days post-procedure is a known and usually self-limited side effect of MFU treatment. It happens because the energy interacts with superficial sensory nerve fibers in transit. The published safety data on Ultherapy (Alster and Tanzi 2015, and several follow-ups) reports that most cases resolve within one to six weeks. My own experience: I had two days of patchy numbness along the jawline on my second procedure that resolved by Day 4 without intervention; on my third procedure I had no numbness at all. Persistent numbness or paresthesia beyond six weeks is uncommon but documented, and it warrants a follow-up call rather than a wait-and-see.

The third tier-two side effect I want to flag is post-inflammatory hyperpigmentation, which is most relevant to darker Fitzpatrick skin types. The published MFU literature describes PIH as uncommon but disproportionately affecting Fitzpatrick IV through VI when device parameters are not adjusted for skin type. Patients report (and the literature supports this) that operator experience with darker skin types matters more than the device itself for PIH risk. If you are Fitzpatrick IV through VI, the question to ask at consultation is not whether the device is safe (it generally is) but whether the operator has experience with your specific skin type and adjusts parameters accordingly. May help, with the caveat that this is a clinic-selection question rather than a treatment-day intervention.

Tier three: rare but real (what the brochure does not foreground)

Tier three is the set of side effects that are rare across published series but real, documented, and worth knowing how to recognize. The brochure version of Ultherapy aftercare tends to gloss over these or mention them in a footnote, which is part of why the patient forums fill in the gap with anxious storytelling. I would rather know the structure than the storytelling. Three of these are worth being clear about.

Motor nerve weakness. The published safety literature describes rare cases of transient motor weakness — typically asymmetric difficulty smiling, eyelid droop, or unequal lower-lip movement — caused by inadvertent deep energy delivery near a motor branch of the facial nerve. The reported incidence across the largest case series is in the fraction-of-a-percent range, and the typical course is resolution within four to twelve weeks without intervention. The clinical detail that matters: motor weakness is a same-day clinic call, not a wait-and-see, because the appropriate response includes documentation, neurology consultation in some cases, and tracking of the recovery curve. I have not experienced this, and I have not personally known anyone who has. The literature describes it. The literature is the right place to learn about it, not the patient forums.

Focal volume loss. A separate set of published case reports describes rare instances of focal volume loss or nodular fibrosis in patients with very thin or lean faces, particularly when SMAS-depth lines are stacked in zones with minimal subcutaneous tissue. The reported incidence is also in the fraction-of-a-percent range, and the typical course varies — some cases resolve, some persist. The clinic protocol that addresses this is parameter adjustment for thin faces and a longer pre-procedure consultation about line placement in lean zones. Patients report (and the literature supports) that this is a clinic-selection and parameter-discussion question, not a device-safety question per se.

Prolonged paresthesia. Numbness or tingling that has not started improving by Day 14 or has not fully resolved by six weeks falls into the rare but real category. Most cases in the published literature resolve within twelve weeks. A small minority do not, and the appropriate response is a follow-up with the treating provider and, if no resolution by twelve to sixteen weeks, a neurology consultation. I have not experienced this either. If you are reading this and you are at week four with persistent numbness, the right move is the follow-up call, not the patient forum.

Comparison table: my three procedures, side effects honestly

Here is the honest tier breakdown across my three procedures (June 2022, October 2024, March 2026). The variables that shifted the side-effect profile most: line count (higher counts produced more swelling and longer Day 1 to Day 3 windows), pre-procedure prep (a clean retinoid pause and good hydration mattered), and operator pacing (the third procedure had brief pauses between line bursts that reduced cumulative tenderness on the jawline).

What does not show up on the side-effect list — but should

There is a category of post-Ultherapy experience that is not exactly a side effect in the clinical sense, but that almost every patient runs into, and that the brochure does not mention because it is more psychological than physiological. I want to name it because the patient forums conflate it with real side effects in a way that makes the forum noise harder to read. Three things in this category are worth being clear about.

The Day 4 disappointment. Ultherapy results do not show up at Day 4. They do not show up at Day 14. They start to be palpable at Month 3, peak at Month 6, and continue to mature through Month 9. Patients who look in the mirror on Day 4 expecting a visible lift and finding only residual pinkness sometimes describe this as a side effect — "the procedure did nothing" — when what is actually happening is that the recovery window is being mistaken for the result window. Studies suggest the collagen-remodeling response is intrinsically slow and the visible result is a Month-3-onward phenomenon. The Day 4 mirror is the wrong instrument for the question.

The Day 21 doubt. Around three weeks post-procedure, when the surface effects have fully resolved and the deep result has not yet emerged, many patients hit a window of doubt about whether the procedure worked. This is the lowest-confidence window in the recovery curve, and it is a window where the temptation to book a second procedure or a different procedure is highest. Patients report (and I support this from my own experience across three procedures) that the right move at Day 21 is to look at the Day 0 photos and wait. The Month 3 photo is when the question gets answered honestly. Booking a corrective intervention at Day 21 is almost always premature.

The expectation mismatch. The brochure version of Ultherapy promises a lift. The real version of Ultherapy delivers a tightening and a slow contour refinement on most faces, and a more pronounced lift on a smaller subset of faces (typically those with mild-to-moderate laxity, intact bone structure, and good skin elasticity baseline). Patients with more advanced laxity who expected a surgical-equivalent result sometimes describe the modest result as a side effect of the procedure failing, when in fact the mismatch was at the consultation stage. May help, with the caveat that this is a clinic-selection and consultation question rather than an aftercare question. The clinics worth using are the ones that walk you through realistic expectations on Day 0 rather than promising a result the device cannot deliver.

What I would actually call my clinic about, and what I would not

The hardest part of side-effect management for foreign patients is the call decision — the question of whether what you are seeing in the mirror at 11pm on Day 2 warrants a same-day call, a follow-up call, or a wait-and-see. I have a sticky-note version of this decision tree that I carry with me. Same-day call: any new motor weakness (asymmetric smile, eyelid droop, unequal lip movement); a welt that has persisted past 72 hours, become painful, or spread; a sudden severe pain in a treated zone that was not there earlier; any sign of infection (warmth, increasing redness, fever, pus). Follow-up call within the week: numbness or tingling that has not started improving by Day 7; new focal indentation that was not there pre-procedure (though wait until Day 21 for a real assessment because transient swelling can mask the underlying contour); a welt or red track that is fading on schedule but you want documentation. Wait-and-see (with photos in case it changes): tier-one swelling and tenderness on the expected timeline; brief patchy numbness that is improving day over day; a Day 4 flush that is fading.

The call protocol I follow is straightforward and worth describing because most clinics have one and most patients do not use it. My Gangnam clinic has a direct WhatsApp number that the coordinator gives me on Day 0 with the written aftercare sheet. I message photos with the date and the timeline. The coordinator routes to the provider for clinical questions. The response time has been within a few hours every time, and on the one occasion my message warranted a follow-up appointment, they slotted me in the next morning. Patients report (and I support this from my own experience) that the clinics worth using are the ones that hand you a written aftercare sheet on Day 0 with a direct messenger number for these calls. If they did not hand you one, ask why on the follow-up appointment.

The other thing about call decisions: the patient forums are not a clinical resource. They are a useful place to read other people's stories and a terrible place to make your own clinical decisions. If something looks different than the timeline I have described or the literature describes, the right move is your clinic, not Reddit. The clinic has parameters, photos from Day 0, and the operator's notes from your specific procedure. Reddit has none of those. May help, with the caveat that I do read the forums occasionally because the human texture is genuinely useful even when the clinical advice is not.

Frequently asked questions

How common are welts after Ultherapy and how long do they last?

Transient welts along transducer pass lines are a known but uncommon side effect, with reported incidence in the low single digits across published series (Alster and Tanzi, 2015). Most welts resolve within 24 to 72 hours with cool compress, no heat, and no active skincare. In my own experience welts have always cleared by Day 3 without intervention. A welt that persists past 72 hours, becomes painful, or spreads warrants a same-day clinic call rather than a wait-and-see.

Is numbness after Ultherapy normal?

Mild patchy numbness or paresthesia in the treated area for a few days is a known and usually self-limited side effect — the energy interacts with superficial sensory nerve fibers. Studies suggest most cases resolve within one to six weeks (Alster and Tanzi, 2015). Persistent numbness beyond six weeks, or any new motor weakness (e.g., difficulty smiling symmetrically), warrants a follow-up call to your provider — that is a different conversation than the routine recovery numbness.

Can Ultherapy cause facial nerve damage?

Transient motor weakness from inadvertent deep energy delivery near a motor branch of the facial nerve is a documented but rare adverse event in the published MFU safety literature, with reported incidence in the fraction-of-a-percent range across the largest case series. Most cases resolve within four to twelve weeks. Any new asymmetric facial movement (uneven smile, eyelid droop, unequal lip movement) post-procedure is a same-day clinic call, not a wait-and-see, because documentation and assessment matter early.

Will Ultherapy cause hyperpigmentation on darker skin?

Post-inflammatory hyperpigmentation is uncommon overall but disproportionately affects darker Fitzpatrick skin types when device parameters are not adjusted for skin type. The MFU literature suggests that operator experience with darker skin matters more than the device itself for PIH risk. If you are Fitzpatrick IV through VI, the consultation question is whether the operator has experience with your specific skin type and adjusts parameters accordingly. Confirm with your specific provider rather than relying on general reassurance.

Can Ultherapy cause facial volume loss?

Focal volume loss or nodular fibrosis is described in published case reports as a rare adverse event, particularly in patients with very thin or lean faces when SMAS-depth lines are stacked in zones with minimal subcutaneous tissue. Reported incidence is in the fraction-of-a-percent range. The clinic-side mitigation is parameter adjustment for thin faces and a longer pre-procedure consultation about line placement. New focal indentation post-procedure should be assessed at the three-to-four-week mark, after transient swelling has resolved.

When should I call my clinic about a side effect versus wait it out?

Same-day call: any new motor weakness, a welt that persists past 72 hours or becomes painful, sudden severe pain in a treated zone, or signs of infection. Follow-up call within the week: numbness that has not started improving by Day 7, or new focal indentation that was not there pre-procedure (assess at Day 21 when swelling has resolved). Wait-and-see with photos: tier-one swelling and tenderness on the expected timeline. The patient forums are not a clinical resource — your clinic is.